Department of Nuclear Medicine, Radboud University Nijmegen Medical Center, the Netherlands.
Cancer. 2011 Oct 15;117(20):4582-94. doi: 10.1002/cncr.26085. Epub 2011 Mar 22.
Indeterminate results at fine-needle aspiration biopsy (FNAB) of thyroid nodules pose a clinical dilemma, because only 20% to 30% of patients suffer from malignancy. Previous studies suggested that the false-negative ratio of [(18)F]-2-fluoro-2-deoxy-D-glucose-positron emission tomography (FDG-PET) is very low; therefore, it may help identify patients who would benefit from (hemi)thyroidectomy. A systematic literature search was performed in 5 databases. After assessment, the identified studies were analyzed for heterogeneity, and the extracted data of test characteristics were pooled using a random-effects model. Threshold effects were examined, and publication bias was assessed. The query resulted in 239 records, of which 6 studies met predefined inclusion criteria. Data from 225 of the 241 described patients could be extracted. There was mild to moderate heterogeneity in study results (inconsistency index [I(2)] = 0.390-0.867). The pooled prevalence of malignancy was 26%. Pooled sensitivity, specificity, positive predictive value, negative predictive value, and accuracy were 95% (95% confidence interval [95% CI], 86%-99%), 48% (95% CI, 40%-56%), 39% (95% CI, 31%-47%), 96% (95% CI, 90%-99%), and 60% (95% CI, 53%-67%), respectively. Sensitivity increased to 100% for the 164 lesions that measured >15 mm in greatest dimension. There was no evidence of threshold effects or publication bias. A negative FDG-PET scan in patients who had thyroid nodules >15 mm with indeterminate FNAB results excluded thyroid cancer in a pooled population of 225 patients. Conversely, a positive FDG-PET result did not identify cancer, because approximately 50% of these patients had benign nodules. The authors concluded that the incorporation of FDG-PET into the initial workup of such patients before surgery deserves further investigation.
甲状腺结节细针抽吸活检(FNAB)的不确定结果带来了临床困境,因为只有 20%至 30%的患者患有恶性肿瘤。先前的研究表明,[(18)F]-2-氟-2-脱氧-D-葡萄糖正电子发射断层扫描(FDG-PET)的假阴性率非常低;因此,它可能有助于识别那些受益于(半)甲状腺切除术的患者。在 5 个数据库中进行了系统的文献检索。评估后,对确定的研究进行了异质性评估,并使用随机效应模型汇总了提取的测试特征数据。检查了阈值效应,并评估了发表偏倚。查询结果产生了 239 条记录,其中 6 项研究符合预定的纳入标准。可以从 241 名描述的患者中的 225 名患者中提取数据。研究结果存在轻度至中度异质性(不一致指数 [I(2)] = 0.390-0.867)。恶性肿瘤的合并患病率为 26%。合并的敏感性、特异性、阳性预测值、阴性预测值和准确性分别为 95%(95%置信区间 [95%CI],86%-99%)、48%(95%CI,40%-56%)、39%(95%CI,31%-47%)、96%(95%CI,90%-99%)和 60%(95%CI,53%-67%)。当最大直径测量>15 毫米的 164 个病变的 FDG-PET 扫描结果为阴性时,敏感性增加到 100%。没有证据表明存在阈值效应或发表偏倚。在 225 名患者中,对直径>15 毫米、FNAB 结果不确定的甲状腺结节进行 FDG-PET 扫描,如果结果为阴性,则可排除甲状腺癌。相反,FDG-PET 结果阳性并不能识别癌症,因为这些患者中约有 50%有良性结节。作者得出结论,在手术前将 FDG-PET 纳入此类患者的初始检查值得进一步研究。